BIOALLIANCE PHARMA (C4X) - Total Liabilities

Latest total liabilities as of December 2023: €20.47 Million EUR

Based on the latest financial reports, BIOALLIANCE PHARMA (C4X) has total liabilities worth €20.47 Million EUR as of December 2023.

Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

BIOALLIANCE PHARMA - Total Liabilities Trend (2016–2023)

This chart illustrates how BIOALLIANCE PHARMA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.

BIOALLIANCE PHARMA Competitors by Total Liabilities

The table below lists competitors of BIOALLIANCE PHARMA ranked by their total liabilities.

Liability Composition Analysis (2016–2023)

This chart breaks down BIOALLIANCE PHARMA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.

Liquidity & Leverage Metrics

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how BIOALLIANCE PHARMA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for BIOALLIANCE PHARMA (2016–2023)

The table below shows the annual total liabilities of BIOALLIANCE PHARMA from 2016 to 2023.